Novacyt S.A.
(“Novacyt”, the “Company” or the “Group”)

Liquidity Agreement Monthly Update and Total Voting Rights

Paris, France, Eastleigh and Manchester, UK – 1 November 2024 – Novacyt (EURONEXT GROWTH: ALNOV; AIM:
NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares
traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity
Agreement is governed by French law and is further summarised below.

During the period from 1 October to 31 October 2024, Invest Securities purchased 35,522 ordinary shares at a
maximum price of €0.76 and a minimum price of €0.63 and sold 29,221 ordinary shares at a maximum price of
€0.80 and a minimum price of €0.64 under the Liquidity Agreement. The total number of ordinary shares in the
Company, which are held in treasury as at close of business on 31 October 2024, is 82,311.

Total Voting Rights

The total number of ordinary shares in the Company is 70,626,248. This figure may be used by shareholders as the
denominator for calculations by which they will determine if they are required to notify their interest in, or a change
to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's
Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial
Conduct Authority under Part VI of FSMA.

Contacts

Novacyt SA https://novacyt.com/investors
Lyn Rees, Chief Executive Officer Via Walbrook PR
Steve Gibson, Chief Financial Officer

SP Angel Corporate Finance LLP (Nominated Adviser and Broker) +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

Deutsche Numis (Joint Broker) +44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Michael Palser

Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or novacyt@walbrookpr.com
Paul McManus / Lianne Applegarth +44 (0)7980 541 893 / +44 (0)7584 391 303
Phillip Marriage / Alice Woodings +44 (0)7867 984 082 / +44 (0)7407 804 654


About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies
and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable
seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health
and environmental.
The Company is divided into three business segments:

Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services
focused on three therapeutic areas:
• Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
• Precision Medicine: DPYD genotyping assay
• Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid
PCR machines, including:
• Ranger® Technology: automated DNA sample preparation and target enrichment
technology
• genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

Research Use Only Range of services for the life sciences industry:
• Design, manufacture, and supply of high-performance qPCR assays and workflows
for use in human health, agriculture, veterinary and environmental, to support
global health organisations and the research industry
• Pharmaceutical research services: whole genome sequencing (WGS) / whole
exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Eastleigh and Manchester),
Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the
London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth (“ALNOV”).

For more information, please refer to the website: www.novacyt.com

Further information on the Liquidity Agreement

On 12 September 2016, the Company and Invest Securities entered into the Liquidity Agreement pursuant to which
Invest Securities provides liquidity services in relation to the ordinary shares to the Company. Invest Securities may
purchase ordinary shares on behalf of the Company under the agreement, subject to approval from Shareholders
as to the price at which ordinary shares can be brought back and the aggregate amount that the Company may
provide to Invest Securities to purchase such ordinary shares.

Shareholder approval was granted at the Shareholders’ meeting held on 18 July 2024 for the purchase of ordinary
shares by Invest Securities under the agreement at a maximum purchase price per ordinary shares of €5.00 for an
aggregate maximum purchase price of €200,000 and for 18 months from the date of the approval. Under the
agreement, Invest Securities must act completely independently of the Company and the Company must not
communicate with the employees of Invest Securities who are responsible for performing the agreement. Invest
Securities is paid €10,000 per annum for its services under the liquidity agreement. The agreement has an initial
term of two years, with a rolling extension of one year thereafter. The agreement can be terminated by either party
at the end of each such period subject to two months’ prior notice. The Liquidity Agreement is governed by French
law. Ordinary shares purchased by Invest Securities are either cancelled or held as treasury shares (which are non-
voting and do not rank for dividends).